Disclaimer: The information provided by Stockify is for educational and informational purposes only and does not constitute investment advice. Stockify is not a SEBI-registered broker, investment advisor, or research analyst. Investments in unlisted shares involve risks. Please consult your financial advisor and conduct your own due diligence before making any investment decision.
Stay ahead of the curve with in-depth articles, IPO alerts, and financial guides for the unlisted market.

CS Setty hints SBI General Insurance may follow the SBI AMC IPO. Here's when investors can expect listings

.jpg.jpeg)
Zepto Valuation may reach $7–8 billion. Explore URDHP details, financials, risks, opportunities, and growth outlook.


Zepto IPO is heating up, the quick commerce giant is set to file its updated DRHP with SEBI next week. Read on for all key details.


Zepto NOV has reached near $1 billion ahead of its IPO. Explore the growth, profitability, timeline, and market position of quick commerce startups.


NSE investor accounts cross 26 crore as retail participation surges beyond metro cities. Read what is driving India’s stock market growth.


SBI Funds Management IPO is set for 2026! Chairman CS Setty confirms D-Street debut. Check IPO size, OFS details, key dates & what investors need to know


NSE recently announced a dividend of Rs 35 per share for its investors. Read the blog for more NSE dividend history in the last 5 years.


S3V Vascular Technologies Limited called an EGM on June 22, 2026 to raise ₹11.51 crore via preferential allotment of 2,09,390 equity shares at ₹550 each.


Comparing and analyzing NSE vs. BSE in terms of financials, operations, and market share and valuation.

.jpg.jpeg)
Zepto share price fell from ₹58 to ₹42 in the unlisted market despite Sebi's IPO nod. Here's why investors are cautious ahead of the ₹9,300 crore listing.

.jpeg)
NSE unlisted shares is in focus ahead of the expected IPO filing. Know the valuation, risks and investment case
1.jpg)

Suzlon share price drops over 2% after SEBI imposes ₹29 crore fine for misleading financial statements. Know what it means for investors.


API Holdings improved margins and cut losses in FY26. Learn what's driving PharmEasy's recovery.
